• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Baxter settles with the SEC for $18M

Baxter settles with the SEC for $18M

February 23, 2022 By Chris Newmarker

BaxterThe U.S. Securities and Exchange Commission announced today that Baxter will pay an $18 million penalty over foreign exchange trading practices that misstated the company’s earnings.

In its annual report out today, Baxter said that it agreed to cease and desist from future violations, though it did not admit or deny the findings in the SEC’s administrative order.

Last year, the company settled a federal shareholders lawsuit over the matter for $16 million.

The SEC found that Baxter violated federal securities law from at least 1995 to 2019 by converting non-U.S. dollar amounts on its financial statements under a convention that was not following generally accepted accounting principles.

Starting in at least 2009, the company exploited the convention to enter into intra-company foreign exchange transactions solely to generate foreign exchange accounting gains or avoid foreign exchange accounting losses, according to the SEC.

Baxter spent $31 million for its internal investigation and related costs in 2021; it spent $23 million in 2020. The company said in early 2020 that the internal probe had found $276 million in overstated income over the years.

“It is critical that companies that identify wrongdoing proactively come forward and cooperate with the SEC staff,” said Paul Montoya, associate regional director of the SEC’s Chicago office.

“Baxter’s self-reporting and substantial cooperation in working with the staff in this complex investigation was an important consideration in assessing the appropriate sanctions for this case,” Montoya said in an SEC news release.

Scott Bohaboy and Jeffrey Schaible, respectively Baxter’s former treasurer and assistant treasurer, also settled with the SEC — with the two agreeing to avoid future violations without admitting or denying wrongdoing. The SEC claims that Schaible and others working under his direction was primarily responsible for the transactions, while Bohaboy supposedly failed to investigate the treasury department’s consistent gains.

Bohaboy will pay a $125,000 civil penalty. Schaible agreed to pay a $100,000 civil penalty, disgorgement of $76,404 and prejudgment interest of $12,955. In addition, the settlement creates a fair fund for distributing settlement proceeds to harmed investors.

 

 

 

 

 

Filed Under: Business/Financial News, Featured, Legal News, News Well, Wall Street Beat Tagged With: Baxter

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy